ClinicalTrials.gg
CompletedNCT04088721Updated Sep 16, 2025

Tolerability and Potential Efficacy of AD17002 in Subjects With Allergic Rhinitis

A Phase 1/2 interventional study of AD17002 and Formulation Buffer in Allergic Rhinitis, sponsored by Advagene Biopharma Co. Ltd.. Completed at 1 site in Taiwan. Open to participants aged 20 Years to 49 Years. Per ClinicalTrials.gov, last updated 2025-09-16.

Sponsored by Advagene Biopharma Co. Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Mar 2019, registered Aug 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
20 Years to 49 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Rhinitis, Allergic with a site in Taiwan — 2 open to participants now, 4 under way, none of them phase 3. Rhinitis, Allergic · Taiwan.

Enrollment
12th of 15
48 · median 60
Started
2019
with 1 other
Phase 1/2
Only one
of the 17
Registered
8th of 17
by date
Lead sponsor
1 of 17
Advagene Biopharma Co. Ltd.

Among the 17 studies in Rhinitis, Allergic with a site in Taiwan, this one is the 12th largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2019, is the only one in phase 1/2, and was the 8th registered.

Rhinitis, Allergic

717 studies on the registry are indexed under Rhinitis, Allergic; 94 are open to participants now.

Browse Rhinitis, Allergic studies →

Open to participants now

2 of the 17 studies in Rhinitis, Allergic with a site in Taiwan are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 54 Rhinitis, Allergic studies recruiting now, 11 (20%) set no upper age limit and 38 (70%) stop at 75 or younger; 22 take children under 18; 13 take healthy volunteers.

This study: 20 Years to 49 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Rhinitis, Allergic with a site in Taiwan, or all of them as a file.
02

Study summary

A single center, double-blind, randomized, dose-escalation study to assess the safety, tolerability and efficacy of 3 doses of AD17002 in comparison to placebo. Subjects will be randomized at 3:1 ratios in each of 3 cohorts to receive AD17002 or placebo.

Read the detailed description

A single center, double-blind, randomized, dose-escalation study to assess the safety, tolerability and efficacy of 3 doses of AD17002 in comparison to placebo. Subjects will be randomized at 3:1 ratios in each of 3 cohorts to receive AD17002 or placebo. The following treatment cohorts are featured in a dose-escalating manner:

A. Cohort 1 will comprise 16 subjects who will receive, in a double-blind manner, either 20 μg AD17002 (n=12) or placebo (n=4) on Study Day 1, 8, and 15.

B. Cohort 2 will comprise 16 subjects who will receive, in a double-blind manner, either 40 μg AD17002 (n=12) or placebo (n=4) on Study Day 1, 8, and 15.

C. Cohort 3 will comprise 16 subjects who will receive, in a double-blind manner, either 60 μg AD17002 (n=12) or placebo (n=4) on Study Day 1, 8, and 15.

A total of 16 subjects in cohort 1 will receive the assigned study preparation before the remainder of the Cohort. Study drug administration to the next subject for the first 8 subjects in the cohort 1 will be separated for at least one day elapse (at least 24 hrs). The progression to the next cohort will take place after the SRT review the whole follow-up period safety data of previous cohort.

03

Conditions studied

  • Allergic Rhinitis

Browse trials for

04

Who can participate

Ages eligible
20 Years to 49 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A subject can participate in the study only if all the following criteria are met:

  1. Subject 20-49 aged years, having a clinical history of allergic rhinitis (diagnosed by a physician) of 1 year duration or more and have received anti-allergy treatment during the previous year before the study enrollment.
  2. Subjects with HDM-specific IgE serum value ≥ 0.7 kUA/L during screening period.
  3. HDM allergic rhinitis symptoms during the baseline period defined as a total nasal symptoms score more than 6, at least on 5 of 7 consecutive calendar days in screening period. A subject receiving anti-allergy medication is required to washout of their medication before and during screening period of the trial until the required symptom threshold is met.
  4. No known prior clinical history of asthma.
  5. Subjects who are of agrees to remain abstinent or use (or have their partner use) an acceptable method of within the projected duration of the trial. Acceptable methods of birth control are: intrauterine device, hormonal contraception, diaphragm with spermicide, contraceptive sponge, condom, vasectomy, as per local regulations or guidelines. Female subjects of must have negative serum pregnancy test at screening, and negative urine pregnancy test at randomization visit.
  6. A female subject who is not of reproductive potential and a male subject who is diagnosed to be sterile is eligible without requiring the use of contraception. A female subject who is not of reproductive potential is defined as: one who has either

    1. Reached natural menopause (defined as 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone levels in the range as determined by the laboratory, or 12 months of spontaneous amenorrhea),
    2. Six weeks postsurgical documented total hysterectomy and/or bilateral salpingo-oophorectomy, or
    3. Bilateral tubal ligation.
  7. Subject or the subject's legal representative understands the trial procedures, alternative treatments available, risks involved with the trial, and voluntarily agrees to participate by giving written .
  8. Be able to read, understand, and complete questionnaires and diaries.
  9. Provide written informed consent for the trial and willing to adhere to dose and visit schedules.

Exclusion criteria

Exclusion Criteria:

Subjects who meet any of the following criteria are not eligible to enter the study:

  1. Has a , known history of symptomatic allergic rhinoconjunctivitis and/or asthma caused by mold, animal hair and dander, or other allergens (except HDM) to which the subject is regularly exposed and sensitized. Subjects without a known history of allergy other than to HDM, but show any positive result (on CAP test) towards the allergens could be accepted in the judgement of the investigator.
  2. Has any nasal condition that, in the judgement of the investigator, could confound the efficacy or safety assessments (e.g., nasal polyposis, nasal malformation, frequent nosebleeds, etc).
  3. Has a history of anaphylaxis reaction to any known or unknown cause.
  4. Has a history of chronic urticaria and/or angioedema within the last 2 years before Screening Visit.
  5. subjects as result of illness (e.g. infection) or treatment.
  6. Has acute respiratory illness needing antibiotics or antivirals within 14 days prior to the Screening visit.
  7. Has acute sinusitis or chronic sinusitis accompanying acute symptoms within 3 days prior to administration of first dose of study drug.
  8. Has any clinically relevant chronic disease (≥3 months duration) [including but not limited to cystic fibrosis, , type I diabetes mellitus, malabsorption or malnutrition, renal or hepatic insufficiency, rheumatic arthritis, lupus and other diseases].
  9. Has documented history of Bell's palsy.
  10. Has a history of allergic reaction to kanamycin.
  11. Has received Immunosuppressive treatment (ATC code L04 or L01) within 3 months prior to the Screening visit.
  12. Has had previous immunotherapy treatment with any HDM allergen.
  13. Has had previous exposure to the study drug or Flu Vaccine AD07030.
  14. Is receiving ongoing treatment with any specific immunotherapy at the time of the Screening Visit.
  15. Has a known history of allergy (except HDM), , or intolerance to medicinal products, rescue medications, or self-injectable epinephrine.
  16. Subjects with chronic (> 6 months) or intermittent dependence on nasal, inhaled, oral, intramuscular, intravenous , or potent topical corticosteroids with systemic effects. Subjects who are non-chronic users and do not use these corticosteroids intermittently must undergo at least 5 half-lives of prior to the Screening visit.
  17. Subjects using other medications for their allergic rhinitis and/or asthma if they cannot abstain from the specified time window below (or 5 half-lives, whichever is longer) prior to the Screening visit:

    • Nasal or oral antihistamines: 48 hours
    • Nasal decongestants: 24 hours
    • Oral decongestants: 24 hours
    • Short acting inhaled beta-agonists: 48 hours
    • Long acting antihistamine (half-life >24hrs): 10 days
  18. Subjects who had chronic use (> 6 months) of concomitant medications [e.g., tricyclic antidepressants, beta-blocker, xanthines (including theophylline, but not including caffeine), anticholinergics, cromoglycates, leukotriene antagonists, 5-lipoxygenase inhibitors and long-acting inhaled beta-agonists, etc] that would affect assessment of the effectiveness of the investigational product. Subjects who are non-chronic users of these medications must undergo at least 5 half-lives of washout prior to the Screening visit.
  19. Is nursing at randomization and within the projected duration of the trial.
  20. Subject who plans travel outside the trial area for a substantial portion of the trial period.
  21. Other cases judged by the investigator to be ineligible for participation in the study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    AD17002 20μg

    Intranasal weekly dosing of AD17002 for three times

    Biological: AD17002

  • Experimental
    AD17002 40μg

    Intranasal weekly dosing of AD17002 for three times

    Biological: AD17002

  • Experimental
    AD17002 60μg

    Intranasal weekly dosing of AD17002 for three times

    Biological: AD17002

  • Placebo comparator
    Placebo

    Intranasal weekly dosing (placebo) for three times

    Other: Formulation Buffer

Interventions

  • BiologicalAD17002

    LTh(αK) as immunomodulator

  • OtherFormulation Buffer

    Formulation buffer

06

What researchers measure

Primary outcomes

  1. Safety and tolerance of AD17002 treatments in patients with HDM allergy as measured by incidence of adverse events

    * Vital signs * Physical examinations * Safety laboratory parameters (hematology and biochemistry) * Urine parameters * Adverse Events (CTCAE) * Nasal Cavity Examination and Tolerability Symptoms Scoring

    Time frame: up to 51 days.

Secondary outcomes

  1. Change in the total nasal symptoms score (TNSS)

    Chang in Sneezing, Rhinorrhea, Nasal congestion / Blockage and Pruritus are recorded in diary and averaged. Severity is graded between 0-3 for each symptom. 0 = no symptoms 1 = mild symptoms (sign/symptom clearly present, but minimal awareness; easily tolerated) 2 = moderate symptoms (definite awareness of sign/symptom that is bothersome but tolerable) 3 = severe symptoms (sign/symptom that is hard to tolerate; causes interference with activities of daily living and/or sleeping)

    Time frame: up to 51 days.

  2. Change in the Rhinitis Daily Medication use Score (DMS)

    Antihistamine oral form (Desloratadine 5mg/day) could be used in the evening, if the total reflective TNSS reaches to 8 points or greater. 4 points addition to subjects take the antihistamine and 0 to subjects do not.

    Time frame: up to 51 days.

  3. Change in the the average of subject-reported combined TNSS and DMS

    Changes in the self-reported TNSS and DMS against baseline.

    Time frame: up to 51 days.

  4. Change in the titers of HDM specific antibodies

    The titers of specific antibodies, IgA, IgE, IgG and IgG4, are measured by ImmunoCap methods(Phadia 100).

    Time frame: up to 51 days.

  5. Change in the titers of Drug specific antibodies.

    The titers of specific antibodies, IgA, IgE and IgG, are measured by ImmunoCap methods(Phadia 100).

    Time frame: up to 51 days.

07

Study locations

1 site
  • Taipei Medical University
    Taipei, Taiwan, Taiwan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2019 to primary completion in Jul 2020, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2019
First posted
Sep 13, 2019
StartActual
Mar 26, 2019
Primary completionActual
Jul 30, 2020
CompletionActual
Dec 11, 2020
Last update
Sep 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04088721
Lead sponsor
Advagene Biopharma Co. Ltd.
Collaborators
Clinipace Worldwide, Taipei Medical University
Responsible party
Sponsor
First posted
Sep 13, 2019
Start date
Mar 26, 2019
Primary completion
Jul 30, 2020
Completion
Dec 11, 2020
Last update
Sep 16, 2025

Study contacts

Hanpin Kuo
principal investigator · Taipei Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Heat-labile enterotoxin, E coli

Start the discussion